Main Article Content

Abstract

Systemic sclerosis (SSc) is uncommon connective tissue disease characterized by a pathological thickening and tethering of the skin and involvement of internal organ (i.e gastrointestinal tract, heart, lungs, and kidneys). Systemic sclerosis seems to result from a multifactorial process (alteration of the immune system, genetic, and  environmental factors) but its pathogenesis remains unclear. A familial history of SSc represents an important risk factor for developing the disease.1 We describe two generations family who developed SSc.

Article Details

How to Cite
Nilasari, D., Hamijoyo, L., Kasjmir, Y. I., & Setiyohadi, B. (2018). Systemic sclerosis in two generations family: a mother and offspring. Indonesian Journal of Rheumatology, 1(1). https://doi.org/10.37275/ijr.v1i1.18

References

  1. Chifflot H, Fautrel B, Sordet C, et al., Incidence and prevalence of
  2. systemic sclerosis: A Systematic Literature Review, Semin Arthritis
  3. Rheum 37:223-235.
  4. Varga J, Denton CP, Systemic sclerosis and the scleroderma-spectrum
  5. disorder in Rudddy S, Harris ED, Sledge CB, Kelley’s Textbook of
  6. Rheumatology, 7th edition, WB Saunders Company Philadelphia 2007,
  7. p:1312.
  8. Feghali CA, Wright TM. Epidemiologic and clinical study of twins with
  9. scleroderma. Arthritis Rheum 1995;38:S308.
  10. Rothfi eld NF, Rodnan GP. Serum antinuclear antibodies in progressive
  11. systemic sclerosis (scleroderma). Arthritis Rheum 1968;11:607.
  12. Maddison PJ, Skinner RP, Pereira RS, et al. Antinuclear antibodies
  13. in the relatives and spouses of patients with systemic sclerosis. Ann
  14. Rheum Dis 1986;45:793.
  15. Arnett FC, Howard RF,Ta F, et al,. Increased prevalence of systemic
  16. sclerosis in a Native American tribe in Oklahoma: Association with an
  17. Amerindian HLA haplotype. Arthritis Rheum 1996;39:1362.
  18. Kuwana M, Okano Y, Kaburaki J, Inoko H. HLA class II genes
  19. associated with anticentromera antibody in Japanese patients with
  20. systemic sclerosis (scleroderma). Ann Rheum Dis 1995;54:983-7.
  21. Ho KT, Reveille JD, The clinical relevance of autoantibodes in
  22. scleroderma, Arthritis Res Ther2003, 5:80-93.
  23. Tashkin DP, Elashoff R. Clements PJ, Goldin J, Roth MD, Furst DE, et
  24. al., Cyclophosphamid versus placebo in scleroderma lung disease N
  25. Engl J Med 2006;354:2655-2666.